Sidero Bioscience Announces Agreement with SRS Life Sciences for Commercialization of BioFe for Iron Deficiency

Sidero Bioscience, LLC, (Hershey, PA) a clinical stage biotechnology company targeting human digestive health, today announces the execution of a term sheet agreement with SRS Life Sciences PTE. LTD, (Singapore) a leading life sciences company. The agreement provides SRS exclusive rights for sales, marketing, and distribution of Sidero’s patented biologic iron, BioFeTM, for the management of iron deficiency and related disorders in India and Southeast Asia.

“This agreement illustrates the excellent partners and licensing opportunities available for our robust and intuitive BioFe technology,” noted Darren Wolfe, Ph.D., President & CEO, Sidero, adding “Iron Deficiency remains a massive global unmet medical need, one that BioFe addresses with natural biology instead of chemicals. We are encouraged by the eagerness of the SRS team to work with us and expect a binding agreement in the near term.”

“At SRS Life Sciences, we exist to change what’s possible for the health of the 6 billion people living in emerging nations. We continuously identify the most pressing unmet healthcare needs so we can be first to deliver products and solutions that lessen the burden of disease,” states Suchet Rastogi, CEO, SRS Life Sciences. Mr. Rastogi continues, “With BioFe, our initial target is to move the needle on the 468 million women suffering from anemia.”

Iron Deficiency (ID), the most common and widespread global nutritional disorder, affects over 2 billion people and causes about 1 million deaths/year (predominantly in Africa/Southeast Asia). The WHO estimates a staggering $2 trillion annual global economic cost due to micronutrient deficiencies, with iron being the most common. ID, which frequently progresses to Iron Deficiency Anemia (IDA), is associated with numerous medical conditions and symptoms, affecting all ages – prenatal to elderly. In the young, ID impedes motor and mental development leading to lifelong physical and cognitive deficiencies. In adults, ID causes fatigue, reduced work capacity, and reduced quality of life among many other symptoms. Iron deficiency is also linked to restless leg syndrome (RLS), hearing deficits, and heart failure and kidney disease morbidity. Significantly, even mild Iron Deficiency leads to decreased physical/athletic performance and also decreased intellectual/cognitive performance.

James Connor, Ph.D., Founder and Chairman of the Sidero Board, states, “In partnership with SRS, we strive to provide a safe, effective, and cost-efficient treatment option for iron deficiency. The SRS health team understands the global impact of ID/IDA and are experts in launching transformational technologies, like BioFe, to fill significant unmet medical needs.”

About Sidero Bioscience

Sidero is advancing disruptive technologies utilizing the patented SiderosorbTM platform that employs nutritional Baker’s yeast, Saccharomyces cerevisiae, to provide therapeutic proteins/complexes to improve human health. BioFeTM is a nutritional yeast strain expressing very high levels of H-Ferritin, FTH1, a natural iron transport and storage protein. An illustrative example of the natural biology of the Ferritin/Iron complex is its presence in human breast milk, providing nursing infants the readily adsorbed iron required for growth and development without gastrointestinal upset. Sidero is currently preparing manuscripts detailing the preclinical and clinical development of BioFe

Reyna Silver Signs Option Agreement for Medicine Springs Project in Nevada

Figure 1: Medicine Springs Location

Figure 1: Medicine Springs Location
Figure 1: Medicine Springs Location
Figure 1: Medicine Springs Location

Figure 2: Carbonate Replacement Deposit Model for Medicine Springs

Figure 2: Carbonate Replacement Deposit Model for Medicine Springs
Figure 2: Carbonate Replacement Deposit Model for Medicine Springs
Figure 2: Carbonate Replacement Deposit Model for Medicine Springs

Figure 3: NLR Exploration Results Medicine Springs

Figure 3: NLR Exploration Results Medicine Springs
Figure 3: NLR Exploration Results Medicine Springs
Figure 3: NLR Exploration Results Medicine Springs

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

TORONTO and HONG KONG, Oct. 05, 2020 (GLOBE NEWSWIRE) — (“Reyna or RSLV”) is pleased to announce that it has entered into a Property Option Agreement with Northern Lights Resources Corp. (“NLR”) on the Medicine Springs silver-lead-zinc project (the “Medicine Springs Project”) located in Elko County, Nevada. The Medicine Springs Project comprises 149 unpatented Federal mineral claims covering 1,189 hectares located in the Ruby Mountains Valley just off the famous Carlin Trend.

The Agreement gives Reyna the ability to earn up to an 80% equity interest in the Project (initial 75% with option to purchase an additional 5%) (the “Option”) subject to expending a total of US$2,439,065 on the Project by December 31, 2023. Upon completion of the Option, Northern Lights and Reyna will enter a Joint Venture to continue exploration and development of the Medicine Springs Project, with Reyna acting as the project’s operator. No upfront payments in either cash or shares are due to either NLR or any other party. See below for the detailed terms.

“While Reyna Silver’s main focus will continue to be our flagship Guigui asset, for which we are awaiting permits to commence a 10,000 meter drill campaign this fall, we are delighted to add Medicine Springs to our portfolio of assets,” said Jorge Ramiro Monroy, President and CEO. Medicine Springs is a Guigui-like CRD system with high-grade silver potential, which lies in Nevada’s CRD elephant country and we are eager to begin applying the same exploration model that led to Arizona Mining’s Taylor Manto and MAG Silver’s Cinco de Mayo discoveries. The Northern Lights team has done an excellent job developing the project to its current near-drill ready stage, which lets us hit the ground running.”

“Figure 1: Medicine Springs Location” is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6669eecf-7969-4d08-8495-284a455679fa

“Figure 2: Carbonate Replacement Deposit Model for Medicine Springs” is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5b835479-ba68-435c-9e1d-ee4d62bb9525

The Medicine Springs Project

The world-famous Carlin Trend runs just east of the Medicine Springs area and prior to acquisition by NLR in 2017, the area was explored for Carlin-style gold potential from 1986-2008 by companies including, US Minerals Exploration, Golden Phoenix, Cominco America and Silver Resources. This exploration work included mapping, sampling, geophysics (CSAMT and IP) and shallow RC drilling. A total of 125 RC holes were drilled on the Project claims (5,380 m with average depth of 43 m, with the deepest hole being 180 m). Limited gold mineralization was found, but significant silver-rich mineralization was cut in several holes including: 33 m @ 90 g/t

Halo Signs Definitive Agreement to Acquire Canmart

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated September 16, 2020 to its short form base shelf prospectus dated September 2, 2020.

Not for Distribution to U.S. Newswire Servicers or For Dissemination in the United States

All figures in CAD unless stated otherwise

Halo Labs Inc. (“Halo” or the “Company“) (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) has entered into a definitive share purchase agreement, (the “Share Purchase Agreement“) pursuant to which the Company, in exchange for up to 72,463,768 common shares of Halo (“Halo Shares“), will acquire all of the issued and outstanding shares of Canmart Ltd. (“Canmart“), a licensed importer and distributor of cannabis-based products for medicinal use (“CBPMs“) in the United Kingdom (“UK“) (the “Acquisition“). Issuance of certain Halo Shares will be subject to milestones and, once issued, will be subject to volume trading restrictions (see “Transaction Overview” below).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201003005004/en/

Canmart operates in a 30,000 square foot storage and distribution facility in Southeast England (Photo: Business Wire)

UK Cannabis Market Overview

The UK population consumes one of the greatest amounts of cannabis per capita in the world. With an estimated 4.7 million cannabis users out of a total general population of 66.4 million in 2019, the number of users per capita even approaches California, currently the single largest cannabis market in the world.1 While the estimated number of people in the UK who use cannabis to treat chronic health conditions is only 1.4 million,2 the legal use of medical cannabis is still in its relative infancy. The UK legalized CPBMs, including plant materials, oils, tinctures, edibles and capsules, in November 2018.

Nearly all CPBM prescriptions are imported, because there is no formal domestic manufacturing program in the UK.3 However, as legal prescriptions are on the rise,4 recent regulations have sought to streamline and ease the importation of medical cannabis to the UK. In March 2020, the Medicines & Healthcare Products Regulatory Agency (the “MHRA“) and the Home Office implemented changes that enable Canmart to import large quantities of CPBMs and hold inventory of these approved medicines. The Company’s research of publicly available information indicates that Canmart and four other companies in the UK currently possess all of the licenses necessary for bulk importation and distribution of CPBMs.

Prohibition Partners anticipates that bulk imports will catalyze demand for CPBM: “As bulk imports increase, so will patient access, driving down the cost of medicines to patients and the National Health Service, improving stability of access, while facilitating an exponential growth in patient numbers.”5 By 2024, the UK medical cannabis market is predicted to be worth nearly £1bn (US$1.3bn), servicing more than 400,000 active patients. With lower costs, easier access and up to fifty-two treatable conditions, Prohibition Partners estimates that the total patient base for